sustained viral response and hematological adverse events in children with chronic hepatitis c

hematological adverse events and sustained viral response in children undergoing therapy for chronic hepatitis c infection

Sustained Viral Response and Hematological Adverse Events in Children With Chronic Hepatitis C

Over the past decades, data from randomized controlled trials have confirmed the use of pegylated in-terferon alpha (peg-IFNα) plus ribavirin (RBV), as the mainstay of HCV therapy in adults (1). In children aged 3 years and older, the Food and Drug administration in the United States did not approve the use of this combination therapy until December 2008, and for children in Europe, approval fr...

Hematological Adverse events and Sustained Viral Response in Children Undergoing Therapy for Chronic Hepatitis C Infection

BACKGROUND Treatment of hepatitis C virus (HCV) infection with interferon (IFN) and ribavirin (RBV) is associated with adverse events, which may affect the patient's adherence to the treatment regimen and the treatment efficacy. OBJECTIVES The aim of this study was to assess the sustained viral response (SVR) and interdependence between the haematological characteristics (leukocyte count, pla...

sustained viral response and hematological adverse events during chronic hepatitis c infection treatment

Sustained Viral Response and Hematological Adverse Events During Chronic Hepatitis C Infection Treatment

Hepatitis C virus (HCV), as a causative agent of chronic liver disease, has infected approximately 175 million people (almost 3%) of the world's population; and 3 to 4 million new cases are added to this figure annually (1). Chronic HCV infection may progress to severe outcomes in the form of cirrhosis and hepatocellular carcinoma (HCC) (2). Currently, there is no effective HCV vaccine on the h...

sustained viral response hematological markers during the treatment of chronic hepatitis c infection in children